Updated
GlaxoSmithKlineGSK · Healthcare
$50.33-0.16%
Market cap$101.0B
IndustryDrug Manufacturers - General
GlaxoSmithKline (GSK) Superinvestor holders
24 of the superinvestors we track hold GlaxoSmithKline (GSK) in their latest 13F filings, $6.7B in total.
Summary
The largest holder is Dodge & Cox, with $2.5B, 1.3% of the portfolio.
In their latest quarter: 4 opened a new position, 6 added, 11 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Dodge & Cox | Trimmed | 48,197,514 | $2.5B | 1.3% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 35,351,693 | $1.7B | 0.5% | Q3 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | 25,182,068 | $1.3B | 0.8% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 4,554,598 | $219M | 0.3% | Q3 2026 |
| Jeremy Grantham GMO |
Added | 3,599,521 | $189M | 0.4% | Q2 2026 |
| Hotchkis & Wiley Hotchkis & Wiley Capital Management |
Trimmed | 3,413,574 | $179M | 0.5% | Q2 2026 |
| Howard Gleicher Aristotle Capital Management |
Trimmed | 4,097,432 | $146M | 0.3% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
New position | 2,652,881 | $139M | 0.2% | Q2 2026 |
| Arrowstreet Capital | Added | 1,633,029 | $86M | 0.0% | Q2 2026 |
| Charles Brandes Brandes Investment Partners, LP |
Added | 1,483,198 | $78M | 0.5% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
New position | 1,019,449 | $53M | 0.0% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Trimmed | 504,171 | $26M | 0.1% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 346,157 | $18M | 0.0% | Q2 2026 |
| Thomas Kahn Kahn Brothers Group |
Trimmed | 158,438 | $8M | 1.3% | Q2 2026 |
| Neil Hennessy Hennessy Advisors |
Held | 122,460 | $6M | 0.2% | Q3 2026 |
| Tweedy, Browne Tweedy, Browne Company |
Trimmed | 77,439 | $4M | 0.3% | Q3 2026 |
| Two Sigma Two Sigma Investments |
New position | 70,993 | $4M | 0.0% | Q2 2026 |
| Richard Pzena Pzena Investment Management |
Added | 28,964 | $1M | 0.0% | Q3 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | 24,046 | $1M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
New position | 23,174 | $1M | 0.0% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Held | 25,000 | $1M | 0.0% | Q3 2026 |
| Hersh Cohen ClearBridge Investments |
Added | 22,625 | $1M | 0.0% | Q2 2026 |
| Sarah Ketterer Causeway Capital Management |
Trimmed | 7,163 | $375,470 | 0.0% | Q2 2026 |
| First Manhattan First Manhattan Co |
Held | 3,941 | $208,380 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 24 |
| Q1 2026 | 23 |
| Q4 2025 | 26 |
| Q3 2025 | 23 |
| Q2 2025 | 21 |
| Q1 2025 | 22 |
| Q4 2024 | 24 |
| Q3 2024 | 26 |
Questions about GlaxoSmithKline
Which superinvestors own GlaxoSmithKline?
24 of the superinvestors we track hold GlaxoSmithKline (GSK) in their latest 13F filings, $6.7B in total. Dodge & Cox, Ken Fisher, PRIMECAP Management, Acadian, Jeremy Grantham, Hotchkis & Wiley.
Who is the largest superinvestor holder of GSK?
The largest holder is Dodge & Cox, with $2.5B, 1.3% of the portfolio.
From GlaxoSmithKline's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.